Luis Eduardo Martínez López
Luis Eduardo Martínez López has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Acela Morales Jackson
Fundación Universitaria de Ciencias de la Salud – Hospital San José de Bogotá
1 shared publication - Andrés Felipe Olaya Rodriguez
Fellow Coloproctología
1 shared publication - Luis Enrique Torres Londoño Torres Londoño
Fellow Coloproctología
1 shared publication - Paola Andrea Arce Peña
Cirugía General
1 shared publication - Yesika Juliana Rubio Acuña
Residente Cirugía General
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Sociedad Argentina de Coloproctologia in Revista Argentina de Coloproctología
- Vol. 37 (3)
Experiencia en el manejo de la fisura anal crónica con esfinterotomía química en 2 centros de alta complejidad en Bogotá: una cohorte descriptiva.
Background: Anal fissure is a condition that significantly impairs quality of life. It can become chronic, in which case hypertonia and spasm of the internal anal sphincter lead to local ischemia. Aim: To describe the experience in the management of patients with chronic anal fissure treated with chemical sphincterotomy using botulinum toxin in two care centers in Bogotá, between January 2017 and December 2023. Design and Methods: A descriptive, retrospective cohort study was conducted by reviewing medical records and collecting sociodemographic, clinical, and outcome variables. The incidence of anal incontinence, recurrence up to six months post-intervention, and persistence of symptoms (proctalgia or bleeding) at 30 days were evaluated, along with the association of botulinum toxin dose and comorbidities. Results: A total of 104 patients were included; the mean age was 48 years, with a predominance of women (63.5%). Among comorbidities, obesity was the most frequent (38.5%), followed by immunosuppression (20.2%). The most common location of the fissure was posterior (61.5%). During follow-up, the recurrence rate was 27.9%. Persistent symptoms included proctalgia in 48.1%, bleeding in 22.1%, and transient fecal incontinence in 8.6% of patients. Conclusion: Chemical sphincterotomy with botulinum toxin for the treatment of chronic anal fissure is an effective and valuable therapeutic alternative with low morbidity rates. Transient fecal incontinence was observed in a minimal proportion of patients. Further studies are warranted to determine the optimal and safest dose to minimize this adverse effect.
- 7 September 2026
- Published by Sociedad Argentina de Coloproctologia in Revista Argentina de Coloproctología
- Vol. 37 (3)
Open AccessExperiencia en el manejo de la fisura anal crónica con esfinterotomía química en 2 centros de alta complejidad en Bogotá: una cohorte descriptiva.
Background: Anal fissure is a condition that significantly impairs quality of life. It can become chronic, in which case hypertonia and spasm of the internal anal sphincter lead to local ischemia. Aim: To describe the experience in the management of patients with chronic anal fissure treated with chemical sphincterotomy using botulinum toxin in two care centers in Bogotá, between January 2017 and December 2023. Design and Methods: A descriptive, retrospective cohort study was conducted by reviewing medical records and collecting sociodemographic, clinical, and outcome variables. The incidence of anal incontinence, recurrence up to six months post-intervention, and persistence of symptoms (proctalgia or bleeding) at 30 days were evaluated, along with the association of botulinum toxin dose and comorbidities. Results: A total of 104 patients were included; the mean age was 48 years, with a predominance of women (63.5%). Among comorbidities, obesity was the most frequent (38.5%), followed by immunosuppression (20.2%). The most common location of the fissure was posterior (61.5%). During follow-up, the recurrence rate was 27.9%. Persistent symptoms included proctalgia in 48.1%, bleeding in 22.1%, and transient fecal incontinence in 8.6% of patients. Conclusion: Chemical sphincterotomy with botulinum toxin for the treatment of chronic anal fissure is an effective and valuable therapeutic alternative with low morbidity rates. Transient fecal incontinence was observed in a minimal proportion of patients. Further studies are warranted to determine the optimal and safest dose to minimize this adverse effect.